¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"whole blood coagulation time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® blood vessel ÇÑ±Û Ç÷°ü
¼³¸í   
  Ç÷¾×ÀÌ ´Ù´Ï´Â ±æ. µ¿¸Æ, ¸ð¼¼Ç÷°ü, Á¤¸ÆÀ¸·Î ±¸¼ºµÈ´Ù. µ¿¸ÆÀº ½ÉÀå¿¡¼­ ³ª°¡´Â ÇǸ¦ ¿î¹ÝÇϴ Ç÷°ü. À̰ÍÀº ½ÉÀå¿¡¼­ ³ª°¡´Â ÇǸ¦ ¿î¹ÝÇϴ Ç÷°üÀ̸砽ÉÀå¿¡¼­ Á÷Á¢ ¸¹Àº ¾Ð·ÂÀ» ¹Þ¾Æ¾ß ÇϹǷΠ¸¹Àº ¿¬Á¶Á÷°ú Åº¼º¼¶À¯·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. À̰ÍÀº Å©±â¿Í ±× Çö¹Ì°æÀû ±¸Á¶¿¡ µû¶ó ´ÙÀ½°ú °°ÀÌ ³ª´«´Ù. ´ëµ¿¸Æ(¿Þ½É½Ç¿¡¼­ Á÷Á¢ ³ª¿À´Â µ¿¸Æ. ¿Â¸öÀÇ Ç÷¾× ¼øÈ¯ÀÇ Áٱ⿪ÇÒÀ» ÇÑ´Ù), µ¿¸Æ(´ëµ¿¸Æ¿¡¼­ ºÐÁö¸¦ ³½ Áß°£ Å©±âÀÇ µ¿¸Æ), ¼¼µ¿¸Æ(µ¿¸Æ¿¡¼­ ºÐÁö¸¦ ³½ ÀÛÀº µ¿¸ÆÀ» ¸»ÇÑ´Ù)À¸·Î ³ª´«´Ù.
  
  ¸ð¼¼Ç÷°ü(capillary)Àº ÇÑÃþÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁø ¾ãÀº Ç÷°ü. À̰ÍÀ» ÅëÇØ¼­ ¿µ¾çºÐ°ú »ê¼ÒÀÇ À̵¿, ³ëÆó¹°ÀÇ À̵¿ µîÀÌ ÀÌ·ç¾îÁø´Ù.
  
  Á¤¸Æ(vein)Àº ½ÉÀåÀ¸·Î µé¾î¿À´Â Çǰ¡ È帣´Â Åë·Î. µ¿¸Æ¿¡ ºñÇØ¼­ Ç÷°üÀÇ º®ÀÌ ¾ã°í Ç÷¾×ÀÇ ¿ª·ù¸¦ ¹æÁöÇϱâ À§ÇÑ ÆÇ¸·ÀÌ Á¸ÀçÇϴ °ÍÀ̠Ư¡ÀÌ´Ù. À̰ÍÀº ½ÉÀå¿¡¼­ Á÷Á¢ ¾Ð·ÂÀ» ¹ÞÁö ¾Ê±â¶§¹®¿¡ Ç÷¾×ÀÌ ¿ª·ùÇÒ ¼öµµ ÀÖ°í ¶Ç Ç÷°üº®ÀÌ ¾ã¾Æµµ µÇ±â ¶§¹®ÀÌ´Ù. Å©±â¿Í Çö¹Ì°æÀû ±¸Á¶¿¡ µû¶ó ´ëÁ¤¸Æ(½ÉÀå°ú Á÷Á¢ ¿¬°áµÇ´Â Á¤¸Æ), Á¤¸Æ(´ëÁ¤¸Æ¿¡ À̸£±âÀü Áß°£ ±½±âÀÇ Á¤¸Æ), ¼¼Á¤¸Æ(¸ð¼¼Ç÷°ü°ú Á÷Á¢ ¿¬°áµÇ¾î Àִ ÀÛÀº ±½±âÀÇ Á¤¸Æ)À¸·Î ³ª´«´Ù.
  
  Ç÷°ü
¿µ¹® blood-brain barrier(BBB) ÇÑ±Û Ç÷³úÀ庮
¼³¸í   
  ³ú¿Í Ã´¼ö¿¡´Â Ç÷·ù·ÎºÎÅÍ ¾î¶² ¹°ÁúÀÌ À¯ÀԵǴ °ÍÀ» ¸·´Â À庮ÀÌ´Ù. À̰ÍÀº ³ú¿Í Ã´¼ö¿¡ Á¸ÀçÇϴ ¸ð¼¼Ç÷°üÀÇ Åõ°ú¼ºÀÌ ºñ±³Àû ´Ù¸¥ ¸ð¼¼Ç÷°üÀÇ Åõ°ú¼ºº¸´Ù ¶³¾îÁö±â ¶§¹®ÀÌ´Ù.
¿µ¹® blood sugar ÇÑ±Û Ç÷´ç
¼³¸í   
  Ç÷¾× ¼Ó¿¡ Æ÷ÇԵǾî Àִ Æ÷µµ´ç. ³ú¿Í ÀûÇ÷±¸ÀÇ ¿¡³ÊÁö¿øÀÌ µÇ°í, ±× ¾çÀº ¿îµ¿, ½Ä»ç µûÀ§¿¡ ÀÇÇÏ¿© ´Þ¶óÁø´Ù. °Ç°­ÀÎÀÇ ¾ÆÄ§ °øº¹½Ã Ç÷Áß Æ÷µµ´ç ³óµµ´Â 60~100mg/dL ÀÌÁö¸¸ ±âŸÀÇ ´çÁú Áï °ú´ç, °¥¶ôÅ佺, 5ź´çÀº ¹Ì·®À̸ç ÀϹÝÀûÀ¸·Î Ç÷´çÀ̶ó Çϸé Ç÷Á߯÷µµ´çÀ» ÀǹÌÇÑ´Ù. Ç÷´çÀº »ýüÀÇ ¿¡³ÊÁö¿øÀ¸·Î¼­ °¡Àå Áß¿äÇÑ ¹°ÁúÀÌ´Ù. ±× ³óµµ´Â Àå°üÀ¸·ÎºÎÅÍÀÇ Èí¼ö, °£¿¡ À־ÀÇ ´ç½Å»ý°ú ±Û¸®ÄÚ°ÕÀÌ ÇÕ¼º-ºÐÇØ, ¸»ÃÊÁ¶Á÷ÀÇ ´çÀÌ¿ë ÄáÆÏÀ¸·ÎºÎÅÍÀÇ ¹è¼³ µî ¿©·¯ ÀÎÀÚ¿¡ ÀÇÇØ Á¿ìµÇ¸ç ±× Á¶Àý¿¡´Â ÀÚÀ²½Å°æ°ú °¢Á¾ È£¸£¸óÀÌ ¹ÐÁ¢ÇϰԠ°ü°èÇÑ´Ù. Æ¯È÷ Ç÷´çÀúÇÏÀÛ¿ë¿¡´Â Àν¶¸°ÀÌ, ±×¸®°í Ç÷´ç»ó½ÂÀÛ¿ë¿¡´Â ¿¡Çdz×ÇÁ¸°, ±Û·çÄ«°ï, ¼ºÀåÈ£¸£¸ó, ºÎ½Å°ÑÁúÈ£¸£¸ó, ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó, °©»ó»ù È£¸£¸óÀÌ °ü°è°¡ ÀÖÀ¸¸ç ±×°ÍµéÀÇ ´ëÇ× ¹× ÇùÁ¶ÀÛ¿ë¿¡ ÀÇÇØ Ç÷´çÄ¡°¡ Á¶ÀýµÈ´Ù.
¿µ¹® blood pressure ÇÑ±Û Ç÷¾Ð
¼³¸í   
  Ç÷¾ÐÀ̶õ Ç÷°ü¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϴ °ÍÀ¸·Î ´ë°³ Æ¯º°ÇÑ ¼³¸íÀÌ ¾øÀ¸¸é µ¿¸ÆÀÇ ¾Ð·ÂÀ» ¸»ÇÑ´Ù. Ç÷¾Ð¿¡´Â ¼öÃà±âÇ÷¾Ð(systolic blood pressure)°ú À̿ϱâÇ÷¾Ð(diastolic blood pressure)ÀÌ ÀÖ´Ù. ¼öÃà±âÇ÷¾ÐÀ̶õ ½ÉÀåÀÌ ¼öÃàÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϰí, À̿ϱâ Ç÷¾ÐÀ̶õ ½ÉÀåÀÌ ÀÌ¿ÏÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÑ´Ù. ´ç¿¬È÷ ¼öÃà±â Ç÷¾ÐÀÌ À̿ϱâ Ç÷¾Ðº¸´Ù ³ô´Ù. Ç÷¾ÐÀ» ¸»ÇÒ ¶§¿¡ ¿¹¸¦ µé¾î 120/80mmHgÀ̶ó°í Àû´Â °ÍÀÇ ¾ÕÀÇ °ÍÀº ¼öÃà±â Ç÷¾ÐÀ» ÀǹÌÇÏ°í µÚ¿¡ Àû´Â 80Àº À̿ϱâ Ç÷¾ÐÀ» ÀǹÌÇÑ´Ù.
¿µ¹® blood ÇÑ±Û Ç÷¾×, ÇÇ
¼³¸í   
  ¼øÈ¯±â, Áï ½ÉÀå°ú Ç÷°ü ¾ÈÀ» ¼øÈ¯Çϴ À¯µ¿¼ºÀÇ Á¶Á÷À» ¸»ÇÑ´Ù. Ç÷¾×Àº Àüü Ã¼ÁßÀÇ ¾à 8%¸¦ Â÷ÁöÇϸç, ºñÁßÀº 1,056~1,059, Á¡µµ´Â ¾à 4.5, pH´Â 7.4ÀÌ´Ù. Ç÷¾×Àº ¾×ü¼ººÐÀΠÇ÷Àå°ú °Å±â¿¡ ¶°µ¹°í Àִ ¼¼Æ÷¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷ÀåÀº Àüü Ç÷¾×ÀÇ 55%¸¦ Â÷ÁöÇϸ砼öºÐ, ´Ü¹éÁú, Ç÷´ç, Áö¹æÁú, ¹«±â¿°·ù, Áú¼ÒÈ­ÇÕ¹°·Î ÀÌ·ç¾îÁø´Ù. ¼¼Æ÷¼ººÐÀº Àüü Ç÷¾×ÀÇ 45%¸¦ Â÷ÁöÇϸç ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. Ç÷¾×ÀÇ ÁÖ¿ä ±â´ÉÀº Àü½Å Á¶Á÷À¸·Î »ê¼Ò¿Í ¿µ¾çºÐ °°Àº ÇÊ¿äÇÑ ¹°ÁúÀ» ¿î¹ÝÇϸ砺ÒÇÊ¿äÇÑ ¹°ÁúÀ» ¹è¼³±â°üÀ¸·Î ¿î¹ÝÇϴ ÀÏÀÌ´Ù. ±× ¹Û¿¡ »ýü¿¡ Çطο°ÁúÀ̳ª ¼¼±ÕÀ» Á¦°ÅÇϰí, ³»ºÎȯ°æÀÇ Çâ»ó¼ºÀ» À¯ÁöÇϸç, Ã¼¿ÂÀ¯Áö¿Í »ýü ¹æ¾î ±â´ÉÀ» ÇÑ´Ù. »ç¶÷ÀÇ Ç÷¾×Àº ¿©·¯ °¡Áö ¼¼Æ÷ Ç÷±¸¿Í ±× ¼¼Æ÷¸¦ Æ÷ÇÔÇϴ ¸¼Àº ¾×üÀΠÇ÷Àå·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷±¸´Â ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ÀûÇ÷±¸´Â ºÓÀº »öÀ» ¶ì´Â ¼¼Æ÷·Î »ê¼Ò¸¦ ¸öÀÇ Á¶Á÷À¸·Î ¿î¹ÝÇϴ ¿ªÇÒÀ» ÇÑ´Ù. Ç÷¼ÒÆÇÀº Ç÷¾×ÀÀ°í¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϴ ¼¼Æ÷ÀÌ´Ù.
  
  ¹éÇ÷±¸´Â Àΰ£ÀÇ ¸é¿ª¿¡ °ü°èÇϴ ¼¼Æ÷À̸砱¸Ã¼ÀûÀ¸·Î ´ÙÀ½°ú °°Àº ¼¼Æ÷µéÀÌ ÀÖ´Ù.
  
  1.°ú¸³±¸(granulocyte): °ú¸³±¸¶õ ¹éÇ÷±¸ÀÇ 60%¸¦ Â÷ÁöÇϸç, ¼¼Æ÷¼Ó¿¡ Æ¯ÀÌÇÑ °ú¸³À» °¡Áö°í Àִ ¼¼Æ÷À̸ç, ´ÙÀ½°ú °°Àº 3°¡ÁöÀÇ ¼¼Æ÷°¡ À̰÷¿¡ Æ÷ÇÔÀÌ µÈ´Ù.
  
    -È£¿°±â±¸(basophil): ¿°±â¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ´Ù. ºÒ±ÔÄ¢ÇÑ ¸ð¾çÀÇ ¼¼Æ÷·Î Çª¸¥ »öÀ» ¶ì´Â °ú¸³ÀÌ ³Ê¹« ¸¹ÀÌ À־ ÇÙÀÌ Àß º¸ÀÌÁö ¾Ê´Â´Ù.
  
    -È£»ê±¸(eosinophil): »ê¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ°í, ´ë°³ ±â»ýÃæÀÇ °¨¿°À̳ª, ¾Ë·¯Áö¿¡¼­ ¸¹ÀÌ Áõ°¡ÇÑ´Ù. ´ë°³ 2°³ÀÇ ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº °ÍÀ¸·Î À̾îÁ® ÀÖ´Ù.
  
    -È£Áß±¸(neutrophil): »ê¼º¿°»ö¾àÀ̳ª ¿°±â¼º¿°»ö¾à¿¡ ÀÇÇÏ¿© ¸ðµÎ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö´Â ¼¼Æ÷·Î ´ë°³ 3°³ÀÇ ÇÙÀ» °¡Áø´Ù. ±×¸®°í ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº ±¸Á¶¹°ÀÌ À־ ÇÙÀ» ¼­·Î À̾îÁÖ°í ÀÖ´Ù.
  
  2.´ÜÇÙ±¸(monocyte): ´Ù°¢Çü¸ð¾çÀ» °¡Áø ¼¼Æ÷·Î °ú¸³À» °¡Áö°í ÀÖÁö ¾Ê´Ù. ¿Ü°è·ÎºÎÅÍ µé¾î¿Â ¹°ÁúÀ» Àâ¾Æ¸Ô´Â ¿ªÇÒ°ú ±×°Í¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇϴ ¿ªÇÒÀ» ÇÏ¿© ¸é¿ª¿¡ °ü°èÇÑ´Ù. À̰ÍÀÌ Ç÷¾× Áß¿¡ Á¸ÀçÇÏÁö ¾Ê°í Á¶Á÷¿¡ °íÁ¤µÇ¾î Àִ °æ¿ì¿¡ À̰ÍÀ» Å«Æ÷½Ä¼¼Æ÷¶ó°í ÇÑ´Ù.
  
  3.¸²ÇÁ±¸(lymphocyte): ÀÛÀº ¿øÇüÀÇ ¼¼Æ÷·Î ¸é¿ª¿¡ ÁßÃßÀûÀΠ¿ªÇÒÀ» ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£
  • atrioventricular conduction time
    ¹æ½ÇÀüµµ½Ã°£
  • acquisition time
    ȹµæ½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • bleeding time
    ÃâÇ÷½Ã°£
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • breath holding time
    ¼ûÂü´Â½Ã°£, È£ÈíÁßÁö½Ã°£
  • circulation time
    ¼øÈ¯½Ã°£
  • clot retraction time
    ÇǶ±µÞ´ç±è½Ã°£, Ç÷º´¼öÃà½Ã°£
  • clotting time
    ÀÀ°í½Ã°£
  • colonic transit time
    ´ëÀåÅë°ú½Ã°£
  • concentration-time curve
    Ç÷Áß³óµµ°î¼±
  • conduction time
    Àüµµ½Ã°£
  • dead time
    ºÒÀÀ½Ã°£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • reaction time
    ¹ÝÀÀ½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • repetition time
    ¹Ýº¹½Ã°£
  • scrub time
    ¼Õ¾Ä´Â½Ã°£
  • survival time
    »ýÁ¸±â°£
  • thrombin time
    Æ®·Òºó½Ã°£
  • transit time
    ÀüÀ̽ð£, Åë°ú½Ã°£
  • voiding time
    ¹è´¢½Ã°£
  • real time ultrasonography
    ½Ç½ÃÃÊÀ½ÆÄÃÔ¿µ¼ú
  • blood
    Ç÷¾×, ÇÇ
  • arterial blood
    µ¿¸ÆÇ÷¾×, µ¿¸ÆÇÇ
  • autologous blood
    ÀÚ°¡Ç÷¾×
  • blood bank
    Ç÷¾×ÀºÇà
  • blood-aqueous barrier
    Ç÷¾×¹æ¼öÀ庮
  • blood-brain barrier
    Ç÷¾×³úÀ庮
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • acquisition time
    ȹµæ½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£
  • atrioventricular conduction time
    ¹æ½ÇÀüµµ½Ã°£
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • bleeding time
    ÃâÇ÷½Ã°£
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • breath holding time
    ¼ûÂü´Â½Ã°£
  • lead-time bias
    Á¶±â¹ß°ß±â°£¹ÙÀ̾
  • clot retraction time
    Ç÷º´ÅðÃà½Ã°£, Çǵ¢À̵ڴç±è½Ã°£
  • clotting time
    (¢¡coagulation time) ÀÀ°í½Ã°£
  • concentration-time curve
    Ç÷Áß³óµµ°î¼±
  • conduction time
    Àüµµ½Ã°£
  • fast time constant circuit
    °í¼Ó½Ã°£°íÁ¤È¸·Î
  • reaction time crossover
    ¹ÝÀÀ½Ã°£±³Â÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gastric emptying time
    À§(êÖ)(³»¿ë(Ò®é»))¹èÃâ½Ã°£(ÛÉõóãÁÊà).
  • gastric emptying time
    À§(³»¿ë)¹èÃâ½Ã°£.
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • half time for saturation
    ¹ÝÆ÷È­±â(ÚâøéûúÑ¢).
  • hardening time
    °æÈ­½Ã°£(¡­ãÁÊà).
  • inertia time
    Ÿ¼º½Ã°£(öçàõãÁÊà)
  • influx time
    À¯ÀԽð£(êüìýãÁÊà).
  • inspiratory pause time
    Èí±âÈÄÈÞÁö½Ã°£.
  • inspiratory phase time
    Èí±â»ó½Ã°£.
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
  • persistence time
    Áö¼Ó½Ã°£(ò¥áÙãÁÊà).
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • whole mount
    ÀüÁ¶Á÷Ç¥º»(îïðÚòÄøöÜâ) Çö¹Ì±â¼ú(úéÚ°Ðüâú) whole muscle[ÇØºÎ]Àüü±ÙÀ°, Àü±Ù(îïÐÉ).
  • whole pelvis irradiation
    Àü°ñ¹ÝÁ¶»ç
  • whole response
    Àü¹ÝÀÀ(îïÚãëë).
  • whole tone
    ÀüÀ½(îïëå).
  • whole-cell recording
    Àü¼¼Æ÷ ±â·Ï
  • blood alcohol level = blood alcohol concentration
    Ç÷Áß¾ËÄڿóóµµ
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • coagulation
    ÀÀ°í(ëêͳ)
  • coagulation
    ÀÀ°í(ëêͳ)
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀÌ»ó(¡­ì¶ßÈ), ÀÀ°íÀå¾Ö(¡­î¡äô).
  • coagulation disorder
    ÀÀ°íÀÌ»ó
  • coagulation factor
    ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • coagulation factor
    ÀÀ°íÀÎÀÚ(¡­ì×í­).
  • coagulation factor
    ÀÀ°íÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mean generation time
    Æò±Õ¼¼´ë±â°£(øÁгá¦ÓáÑ¢Êà)
  • recovery time
    ȸ¼ö ½Ã°£(üÞâ¥ãÁÊà)
  • relaxation time
    ÀÌ¿Ï ½Ã°£(ì¬èÐãÁÊà)
  • residence time
    µ¿°Å ½Ã°£(ÔÒËÜãÁÊà)
  • resolving time
    "ºÐ¸®½Ã°£, ÇØ»ó½Ã°£"
  • retention time
    ¸Ó¹«¸§ ½Ã°£
  • rotational relaxation time
    ȸÀü À̿Ͻð£(üÞï®ì¬èÐãÁÊà)
  • thermal death time
    ¿­»ç½Ã°£ (æðÞÝãÁÊà)
  • time constant
    ½Ã°£»ó¼ö (ãÁÊàßÈâ¦)
  • time constant of a reaction
    ¹ÝÀÀ ½Ã°£»ó¼ö (ÚãëëãÁÊàßÈâ¦)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • transient time
    °úµµ±â ½Ã°£(ΦԤѢãÁÊà)
  • turnover time
    Àüȯ½Ã°£(ï®üµãÁÊà)
  • zero time binding DNA
    ¿µ½Ã(çÍãÁ) °áÇÕ(Ì¿ùê) DNA
  • zero time control
    ¿µ½Ã(çÍãÁ) ´ëÁ¶(ÓßðÎ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • white blood cell
    ¹éÇ÷±¸
  • acquisition time
    ȹµæ½Ã°£
  • arm to lung time test
    ÆÈÆó¼øÈ¯½Ã°£½ÃÇè
  • correlation time
    »ó°ü½Ã°£
  • data acquisition time
    ÀÚ·áȹµæ½Ã°£
  • delay time
    Áö¿¬½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • doubling time
    ¹è°¡½Ã°£
  • echo time [=TE]
    ¿¡Äڽð£
  • elapsed time
    °æ°ú½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Á¶ ½Ã°£
  • fast time constant circuit
    °í¼Ó½Ã°£°íÁ¤È¸·Î
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • half-life; half-time
    ¹Ý°¨±â
  • intercostal real-time scanning
    ´Á°£ ½Ç½Ã°£½ºÄµ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TT tablet triturate; tactile tension; tendon transfer; test tube; testicular torsion; tetanus toxin; te...
WBAPTT whole blood activated partial thromboplastin time
WBCT whole-blood clotting time
WBPTT whole-blood partial thromboplastin time
WBRT whole-blood recalcification time
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ILC Interstitial Laser Coagulation
LACI Lipoprotein Associated Coagulation Inhibitor
MCT Microwave coagulation therapy
PMCT Percutaneous microwave coagulation therapy
DIC diffuse intravascular coagulation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • area under the concentration-time curve
    Ç÷Áß ³óµµ °î¼±ÇÏ ¸éÀû, Ç÷Áß ¾à¹° ³óµµ °î¼±ÇÏ ¸éÀû
  • arm to lung time test
    ÆÈ Æó ¼øÈ¯ ½Ã°£ ½ÃÇè
  • arm-to-retina circulation time
    ÆÈ ¸Á¸· ¼øÈ¯ ½Ã°£
  • bleeding time test
    ÃâÇ÷ ½Ã°£ ½ÃÇè
  • chair time
    Áø·á ½Ã°£, Ä¡·á ½Ã°£
    ȯÀÚ°¡ Áø´Ü ¹× Ä¡·á ¹Þ±â À§ÇÑ ½Ã°£.
  • change over time
    ½Ã°£¿¡ µû¸¥ º¯È­
  • contact time
    Á¢ÃË ½Ã°£
  • correlation time
    »ó°ü ½Ã°£
  • doubling time
    ¹è°¡ ½Ã°£
  • echo time
    ¿¡ÄÚ ½Ã°£
  • exposure time per session
    ´ÜÀ§´ç ³ëÃ⠽ð£
  • fast time constant circuit
    °í¼Ó ½Ã°£ °íÁ¤ ȸ·Î
  • first-time dental patient
    óÀ½ ³»¿øÇÑ È¯ÀÚ
  • hardening time
    °æÈ­ ½Ã°£
    Ä¡°ú¿ë ÀλóÀç ¶Ç´Â ¼®°í°¡ µüµüÇÏ°Ô ±»´Âµ¥ °É¸®´Â ½Ã°£.
  • heating and cooling temperature-place-time profile
    °¡¿­ ¹× ³Ã°¢ ¿Âµµ-À§Ä¡-½Ã°£ Çü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
activated clotting time The most common test used for coagulation time in cardiovascular surgery.
(05 Mar 2000)
activated partial thromboplastin time The time needed for plasma to form a fibrin clot following the addition of calcium and a phospholipid reagent; used to evaluate the intrinsic clotting system.
(05 Mar 2000)
A-H conduction time Forward conduction of the cardiac impulse from atria to ventricles via the A-V node or any bypass tract, represented in the electrocardiogram by the P-R interval. P-H conduction time is from the onset of the P wave to the first high frequency component of the His bundle electrogram (normally 119 ± 38 msec); A-H conduction time is from the onset of the first high frequency component of the atrial electrogram to the first high frequency component of the His bundle electrogram (normally 92 ± 38 msec); P-A conduction time is from the onset of the P wave to the onset of the atrial electrogram (normally 27 ± 18 msec).
(05 Mar 2000)
association time Time elasping between a stimulus and the verbalised response to it.
(05 Mar 2000)
biologic time The concept that our appreciation of time varies with age and is governed by the neural organization of the individual; it obeys a logarithmic rather than an arithmetic law.
(05 Mar 2000)
bleeding time <haematology> A test which measures the time it takes for small blood vessels to close off and bleeding to stop. Abnormal results can be seen in those with congenital or acquired platelet function disorders or thrombocytopenia.
(27 Sep 1997)
P-A conduction time See: atrioventricular conduction.
(05 Mar 2000)
generation time <cell biology> Time taken for a cell population to double in numbers and thus equivalent to the average length of the cell cycle.
(18 Nov 1997)
reaction time The time from the onset of a stimulus until the organism responds.
(12 Dec 1998)
real-time ultrasonography Rapid serial ultrasound images produced using a phased array or scanning transducer; produces a video display of organ motion, such as heart valve or foetal motion.
(05 Mar 2000)
recognition time The interval between the application of a stimulus and the recognition of its nature.
(05 Mar 2000)
partial thromboplastin time Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy.
(12 Dec 1998)
relaxation time Time taken for a system to return to the resting or ground state or a new equilibrium state following perturbation. Often used in context of receptor systems that have a refractory period after responding and then relax to a competent state. Can be used more precisely to mean the time for a system to change from its original equilibrium value to 1/e of this original value.
(18 Nov 1997)
median time to elimination <pharmacology> The time it takes one half of a drug to be eliminated from the body.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • blood test
    Ç÷¾×°Ë»ç
  • blood transgusion
    ¼öÇ÷¹ý !
  • blood vessel
    Ç÷°ü öÇ
  • blue blood
    ¸í¹®(ÇǺΰ¡ Èñ°í Á¤¸ÆÀÌ ºñÃÄ º¸ÀÌ´Â µ¥¼­);±ÍÁ·
  • dragon's blood
    ±â¸°Ç÷(¿ëÇ÷¼ö)ÀÇ ¿­¸Å¿¡¼­ äÃëÇÑ ¼öÁö;¿Í´Ï½º µîÀÇ Âø»öÁ¦)
  • first blood
    ÃÖÃÊ·Î ÃâÇ÷½Ã۱â;ÃʹÝÀÇ ¿ì¼¼
  • full blood
    ¼øÁ¾ÀÇ »ç¶÷
  • half blood
    À̺¹,¹è(´Ù¸¥)°ü°è
  • half blood
    ¹è´Ù¸¥;¾¾´Ù¸¥
  • half blood
    (ÇüÁ¦,ÀڸŰ¡)¹è(¾¾)°¡ ´Ù¸§;¹è(¾¾) ´Ù¸¥ ÇüÁ¦(ÀÚ¸Å)
  • heart's blood
    ½ÉÀå³»ÀÇ Ç÷¾×;½ÉÇ÷;»ý¸í;Áø½É;»ý¸í·Â;¼ÒÁßÇÑ °Í
  • high blood pressure
    °íÇ÷¾Ð
  • ill blood
    ¾ÇÀÇ;¾Ó½É;Àû´ë½É;¿øÇÑ
  • new blood
    (»õ·Î¿î Ȱ·Â(»ç»ó)ÀÇ ¿øÃµÀ¸·Î¼­ÀÇ)ÀþÀºÀ̵é;½ÅÀεé
  • red blood cell(corpuscle)
    ÀûÇ÷±¸
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á